Enveric Biosciences is a biotechnology company focused on developing innovative therapies for various mental health conditions and neurological disorders
The company leverages its expertise in cannabinoid science and psychedelic research to explore novel treatment options, aiming to address significant unmet healthcare needs. By combining advanced technology with a commitment to scientific rigor, Enveric seeks to deliver safer and more effective solutions that can improve patient outcomes and enhance the quality of life for individuals suffering from these challenging conditions.
Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders.
Psychedelics biotech company Enveric Biosciences (NASDAQENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being held at the Hilton Boston Back Bay in Boston, Massachusetts on Sept. 24-26, 2024. EB-003 is a neuropathogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that showed beneficial outcomes in preclinical models of anxiety and depression. The move follows the company's July announcement of positive pre-clinical results of its EB-003 drug candidate to be delivered via oral administration. The results indicated that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses.
